| Source: |
| Type: |
| Tumor cell proliferation is a key characteristic of cancer. It refers to the rapid and uncontrolled growth of cells that can lead to the formation of tumors. |
| 8019- | itraC, | Itraconazole Inhibits AKT/mTOR Signaling and Proliferation in Endometrial Cancer Cells |
| - | in-vitro, | Endo, | AN3CA | - | in-vitro, | Endo, | HEC-1A | - | in-vitro, | Endo, | HEC-50B | - | in-vitro, | Endo, | SNG-II |
| 8014- | itraC, | Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | NA |
| 2180- | itraC, | Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent |
| - | Review, | Var, | NA |
| 8038- | IVM, | Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction |
| - | in-vitro, | PC, | NA |
| 8029- | IVM, | Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? |
| - | Review, | Var, | NA |
| 8028- | IVM, | Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential |
| - | Review, | Var, | NA |
| 8025- | IVM, | Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth |
| - | in-vitro, | CRC, | SW480 | - | in-vivo, | CRC, | HCT116 |
| 8024- | IVM, | Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway |
| - | vitro+vivo, | ESCC, | KYSE-30 | - | in-vitro, | ESCC, | NE3 |
| 8022- | IVM, | Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage |
| - | vitro+vivo, | RCC, | NA |
| 8052- | IVM, | rMETase, | Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Nor, | Hs27 |
| 8040- | IVM, | Ivermectin, a potential anticancer drug derived from an antiparasitic drug |
| - | Review, | Var, | NA |
| 1167- | IVM, | The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer |
| - | vitro+vivo, | NA, | NA |
| 7892- | IVT, | Isovitexin attenuates tumor growth in human colon cancer cells through the modulation of apoptosis and epithelial-mesenchymal transition via PI3K/Akt/mTOR signaling pathway |
| - | in-vitro, | Nor, | HCEC 1CT | - | in-vivo, | Colon, | NA |
| 8007- | JG, | Juglone reduces growth and migration of U251 glioblastoma cells and disrupts angiogenesis |
| - | in-vitro, | GBM, | U251 |
| 8006- | JG, | VitC, | Juglone-ascorbate treatment enhances reactive oxygen species mediated mitochondrial apoptosis in pancreatic cancer |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | Bxpc-3 |
| 8004- | JG, | TP53 Is a Potential Target of Juglone Against Colorectal Cancer: Based on a Combination of Molecular Docking, Molecular Dynamics Simulation, and In Vitro Experiments |
| 8003- | JG, | doxoR, | A juglone derivative that disrupts mitochondrial redox metabolism, inhibiting the breast fibroblast-cancer cell pro-migratory signaling induced by doxorubicin |
| - | in-vitro, | BC, | NA |
| 8002- | JG, | Identification and Biological Evaluation of Juglone-Derived STAT3 Inhibitors against Colorectal Cancer |
| - | in-vitro, | PC, | NA | - | in-vitro, | CRC, | NA |
| 7963- | JG, | Pin1 Inhibitor Juglone Exerts Anti-Oncogenic Effects on LNCaP and DU145 Cells despite the Patterns of Gene Regulation by Pin1 Differing between These Cell Lines |
| - | vitro+vivo, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 5117- | JG, | https://pubmed.ncbi.nlm.nih.gov/31283929/ |
| - | vitro+vivo, | Liver, | NA |
| 974- | JG, | Juglone down-regulates the Akt-HIF-1α and VEGF signaling pathways and inhibits angiogenesis in MIA Paca-2 pancreatic cancer in vitro |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 1918- | JG, | ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro |
| - | in-vitro, | Liver, | HepG2 | - | in-vivo, | NA, | NA |
| 1923- | JG, | Mechanism of Juglone-Induced Cell Cycle Arrest and Apoptosis in Ishikawa Human Endometrial Cancer Cells |
| - | in-vitro, | Endo, | NA |
| 1922- | JG, | Juglone induces apoptosis of tumor stem-like cells through ROS-p38 pathway in glioblastoma |
| - | in-vitro, | GBM, | U87MG |
| 8087- | KAE, | Therapeutic Importance of Kaempferol in the Treatment of Cancer through the Modulation of Cell Signalling Pathways |
| - | Review, | Var, | NA |
| 8091- | KAE, | Kaempferol sensitizes cell proliferation inhibition in oxaliplatin-resistant colon cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT-29 |
| 8092- | KAE, | Kaempferol Reverses Aerobic Glycolysis via miR-339-5p-Mediated PKM Alternative Splicing in Colon Cancer Cells |
| - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Colon, | DLD1 |
| 8096- | KAE, | 5-FU, | Synergistic effect of kaempferol and 5‑fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway |
| - | in-vitro, | CRC, | HCT8 | - | in-vitro, | CRC, | HCT8 |
| 8099- | KAE, | LT, | CHr, | Kaempherol and Luteolin Decrease Claudin-2 Expression Mediated by Inhibition of STAT3 in Lung Adenocarcinoma A549 Cells |
| - | in-vitro, | Lung, | A549 |
| 8101- | KAE, | Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway |
| - | vitro+vivo, | ESCC, | KYSE150 | - | vitro+vivo, | ESCC, | Eca109 |
| 8102- | KAE, | Kaempferol inhibits gastric cancer tumor growth: An in vitro and in vivo study |
| - | vitro+vivo, | GC, | MKN-28 | - | vitro+vivo, | GC, | SGC-7901 | - | in-vitro, | GC, | GES-1 |
| - | in-vitro, | Ovarian, | A2780S |
| 8061- | KAE, | Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway |
| - | in-vitro, | Ovarian, | A2780S | - | in-vitro, | Ovarian, | OVCAR-3 |
| 8065- | KAE, | Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | HCT116 |
| 8067- | KAE, | Cisplatin, | Kaempferol Induces Cell Death and Sensitizes Human Head and Neck Squamous Cell Carcinoma Cell Lines to Cisplatin |
| - | in-vitro, | HNSCC, | NA |
| 8072- | KAE, | Natural defense against colorectal cancer: the effects of kaempferol on epigenetics, apoptosis, inflammation, oxidative stress, and cell proliferation |
| - | Review, | CRC, | NA |
| 8075- | KAE, | QC, | Systematic review on anticancer potential of Kaempferol and quercetin against lung, breast, and colorectal cancers with emphasis on in vitro and in vivo studies |
| - | Review, | Var, | NA |
| 8076- | KAE, | Kaempferol suppresses prostate cancer metastasis and tumor angiogenesis via disrupting the LIMK1/Cofilin pathway |
| - | in-vivo, | Pca, | NA |
| 8077- | KAE, | Kaempferol exerts anti-colorectal cancer effects through its multi-target mediated glucose metabolism remodeling |
| - | in-vitro, | CRC, | NA |
| 8078- | KAE, | Kaempferol induces mitophagy and disrupts iron metabolism via SFXN2 leading to apoptosis in multiple myeloma cells |
| - | in-vitro, | Mye, | NA |
| 8079- | KAE, | Endoplasmic Reticulum Stress-Mediated Apoptosis Induced by Kaempferol in Colorectal Cancer Cells |
| - | in-vitro, | CRC, | DLD1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HUH7 | - | in-vitro, | Cerv, | HeLa |
| 8115- | LA, | Inhibitory Effect of Vaginal Lactobacillus Supernatants on Cervical Cancer Cells |
| - | in-vitro, | Cerv, | CaSki |
| 8147- | Lae, | Mechanisms underlying the therapeutic effects of Amygdalin in treating Cervical Cancer based on multi-omics analysis |
| - | in-vitro, | Cerv, | Ca9-22 | - | in-vitro, | Cerv, | HeLa |
| 863- | Lae, | Amygdalin inhibits the growth of renal cell carcinoma cells in vitro |
| - | in-vitro, | RCC, | NA |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | SK-HEP-1 |
| 8156- | lamb, | A review on chemistry, source and therapeutic potential of lambertianic acid |
| - | Review, | Var, | NA |
| 8162- | LapC, | Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2 |
| - | in-vitro, | Melanoma, | MEL526 | - | in-vitro, | Melanoma, | MEL697 | - | in-vitro, | Melanoma, | MEL103 |
| 8164- | LapC, | Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II |
| - | vitro+vivo, | GBM, | NA |
| 8232- | LCA, | Licochalcone A induces G2/M phase arrest and apoptosis via regulating p53 pathways in esophageal cancer: In-vitro and in-vivo study |
| - | vitro+vivo, | ESCC, | NA |
| 8233- | LCA, | Licochalcone A induces cell cycle arrest and apoptosis via suppressing MAPK signaling pathway and the expression of FBXO5 in lung squamous cell cancer |
| - | in-vitro, | Lung, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:327 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid